Model‐Informed First‐In‐Human Dose Selection for AZD2796, a High‐Affinity Anti‐LILRB2 Antibody
6 affiliations
- 1Early Oncology DMPK AstraZeneca Plc Cambridge UK
- 2Integrated BioAnalysis AstraZeneca Pharmaceuticals LP Gaithersburg Maryland USA
- 3Early Oncology R&D, ICC AstraZeneca Plc Cambridge UK
- 4CPSS AstraZeneca Plc Cambridge UK
- 5Early Global Development AstraZeneca Pharmaceuticals LP Waltham Massachusetts USA
- 6Global Clinical Development AstraZeneca Pharmaceuticals LP Gaithersburg Maryland USA
Abstract
AZD2796 is a humanized anti‐LILRB2 monoclonal antibody designed to promote immune activation by inhibiting LILRB2 on myeloid cells. Because AZD2796 does not bind cynomolgus monkey or rodent LILRB2, conventional approaches to first‐in‐human dose selection were limited. An affinity‐based minimum anticipated biological effect level (MABEL) approach would predict a very low starting dose despite the potential for substantial target‐mediated drug disposition (TMDD). To support dose selection, pharmacokinetic and receptor occupancy (PK‐RO) models were developed using AZD2796 pharmacokinetics in cynomolgus monkeys and TMDD data estimated from a cynomolgus‐reactive surrogate anti‐LILRB2 antibody. An alternative approach using neonatal Fc receptor‐ and LILRB2‐transgenic mouse models was also explored. The cynomolgus surrogate model predicted substantial TMDD at low doses and supported an intravenous starting dose of 30 mg every 3 weeks (Q3W) that was predicted to maintain peripheral LILRB2 occupancy. The model further predicted that approximately 300 mg Q3W would maintain > 95% tumor LILRB2 occupancy under conservative assumptions regarding target burden and tumor exposure. Model performance was supported by the model's ability to reproduce the clinically observed PK and RO characteristics of other anti‐LILRB2 antibodies. The transgenic mouse approach was less robust and generally predicted higher dose requirements. These findings demonstrate that surrogate antibody PK‐RO modeling can support the selection of a pharmacologically active first‐in‐human starting dose for therapeutic antibodies that lack cross‐reactivity with standard preclinical species.
Related
- Clonal tree frequency analysis reveals affinity determinants and enables antibody lead optimization
- Optimal Maturation Protocols for High-Affinity Antibody Targets: A Path-Integral Approach
- CIR-DDG: backbone-agnostic residual correction of antibody-antigen affinity changes with explicit cross-chain geometry
- Antibody-Antigen Affinity Prediction with Chain-Aware Protein Language Modeling
- A blinded, prospective benchmark of in silico antibody discovery anchored to experimental affinity and developability
BibTeX
@article{penney2026modelinformed,
title = {{Model‐Informed First‐In‐Human Dose Selection for AZD2796, a High‐Affinity Anti‐LILRB2 Antibody}},
author = {Mark Penney and Sofia Ferreira and Karla Maloveste and Steven Eck and Amanda Watkins and Georgina Bowyer and Massimiliano Mellone and Adam Hey and Nelson Liu and Fernanda Arnaldez and Des Jones},
journal = {CPT: Pharmacometrics \& Systems Pharmacology},
year = {2026},
month = nov,
doi = {10.1002/psp4.70375},
url = {https://doi.org/10.1002/psp4.70375},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Model‐Informed First‐In‐Human Dose Selection for AZD2796, a High‐Affinity Anti‐LILRB2 Antibody
AU - Mark Penney
AU - Sofia Ferreira
AU - Karla Maloveste
AU - Steven Eck
AU - Amanda Watkins
AU - Georgina Bowyer
AU - Massimiliano Mellone
AU - Adam Hey
AU - Nelson Liu
AU - Fernanda Arnaldez
AU - Des Jones
PY - 2026
DA - 2026/11/08
JO - CPT: Pharmacometrics & Systems Pharmacology
DO - 10.1002/psp4.70375
UR - https://doi.org/10.1002/psp4.70375
AB - AZD2796 is a humanized anti‐LILRB2 monoclonal antibody designed to promote immune activation by inhibiting LILRB2 on myeloid cells. Because AZD2796 does not bind cynomolgus monkey or rodent LILRB2, conventional approaches to first‐in‐human dose selection were limited. An affinity‐based minimum anticipated biological effect level (MABEL) approach would predict a very low starting dose despite the potential for substantial target‐mediated drug disposition (TMDD). To support dose selection, pharmacokinetic and receptor occupancy (PK‐RO) models were developed using AZD2796 pharmacokinetics in cynomolgus monkeys and TMDD data estimated from a cynomolgus‐reactive surrogate anti‐LILRB2 antibody. An alternative approach using neonatal Fc receptor‐ and LILRB2‐transgenic mouse models was also explored. The cynomolgus surrogate model predicted substantial TMDD at low doses and supported an intravenous starting dose of 30 mg every 3 weeks (Q3W) that was predicted to maintain peripheral LILRB2 occupancy. The model further predicted that approximately 300 mg Q3W would maintain > 95% tumor LILRB2 occupancy under conservative assumptions regarding target burden and tumor exposure. Model performance was supported by the model's ability to reproduce the clinically observed PK and RO characteristics of other anti‐LILRB2 antibodies. The transgenic mouse approach was less robust and generally predicted higher dose requirements. These findings demonstrate that surrogate antibody PK‐RO modeling can support the selection of a pharmacologically active first‐in‐human starting dose for therapeutic antibodies that lack cross‐reactivity with standard preclinical species.
SN - 2163-8306
ER -